Skip to content

Author

Zhen Yao

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#explainable ai Review Open access Sep 2026

Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation

Non-small cell lung cancer (NSCLC) is characterized by profound biological heterogeneity, frequently leading to late-stage diagnosis, recurrence, or metastasis. Conventional clinical pathways heavily depend on subjective visual interpretations, invasive tissue biopsies, and experience-based medical models that constrain individualized precision medicine. Identifying noninvasive, cross-scale tools for whole-disease-course assessment is critical for optimizing clinical decision-making and survival outcomes. This review critically synthesizes recent research progress and core algorithmic applications of artificial intelligence (AI) across the diagnostic, therapeutic, and prognostic continuum of NSCLC. In diagnostics, AI models enable rapid morphological screening and tumor subtyping on digital pathology slides, whereas multimodal imaging radiomics extracts microscopic features from macroscopic CT, PET/CT, and MRI scans to noninvasively identify tumor heterogeneity and map metastatic risk. Therapeutically, machine learning and large language models predict treatment responses, characterize tumor microenvironment dynamics, optimize perioperative surgical strategies, and accelerate drug discovery by screening chemical databases and decoding candidate drug mechanisms. Prognostically, multiscale fusion models integrate liquid biopsies, pathomics, radiomics, and clinical records to provide precise risk stratification for recurrence and survival outcomes. While AI has demonstrated transformative potential across the entire clinical lifecycle of NSCLC, significant technical bottlenecks remain, including severe data heterogeneity across healthcare institutions, the lack of clinical transparency in end-to-end “black box” architectures, and low-throughput biological validation. Future research must focus on standardizing data protocols, improving explainable AI, and incorporating multidimensional time series data to realize true intelligent precision medicine.

Shuai-Yu Zheng, Chi Lv, Zhen Yao · 0 citations
Review Open access Jul 2026

Combination and sequential therapy for postmenopausal osteoporosis: recent advances and clinical practice

Combined and sequential therapies represent promising approaches for improving the management of PMO by maximizing therapeutic efficacy while minimizing adverse effects and the potential roles of genomics, bone metabolism biomarkers, and artificial intelligence in supporting personalized treatment strategies are discussed.

Jia-Zhen Liu, Yuqing Hu, Zhen Yao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.